Johnson & Johnson company Veridex will help array-based molecular diagnostics company Nuvera Biosciences market two cancer assays worldwide, Nuvera said last week.

Under the terms of the deal, Veridex will commercialize Nuvera's tests for predicting patient response to tamoxifen and taxane-containing chemotherapy in breast cancer.

The assays are currently still in development, and Nuvera is working to discover and validate signatures for the assay. The agreement with Veridex is also open to future tests in as-yet unknown indications.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.